ATHLONE, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq: INNL ), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that it will report second quarter financial results before the open of U.S. financial markets on August 17, 2016. Innocoll management will host a webcast and conference call at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
Interested parties may access the live webcast and call through the Investors section of the company website at www.innocoll.com or directly through the registration link . A recording will be archived on the company website for 90 days.
The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A telephone replay of the call will be available until 11:59 p.m. EDT on August 20, 2016 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 89801826 .
About Innocoll Holdings plc
Innocoll is a global, commercial-stage, specialty pharmaceutical company that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL® for the treatment of postoperative pain; COGENZIA (INL-002), a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native collagen products —from extraction/purification of type-1 collagen through final delivery form — are manufactured at our certified, integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com . CollaRx ® , Collatamp ® , COLLAGUARD ® , Collieva ® , CollaCare ® , Collexa ® , COGENZIA ® LidoColl ® , LiquiColl ® , and XARACOLL® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.
Contact: Pepe Carmona Chief Financial Officer (215) 983-3362 pcarmona@innocoll.com Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 jsorenson@innocoll.com
